|
|
Haorui supplies
Amisulpride API (Active
Pharmaceutical Ingredient) to pharmaceutical industry, our
Amisulpride API API is produced by
FDA approved cGMP
facility.
Haorui supply APIs
from small R&D to large commercial quantity,
for
product and supply detail please contact us.
|
|
Amisulpride Patents |
|
1 |
7,312,233 |
Amide
derivatives as ion-channel ligands and
pharmaceutical compositions and methods of
using the same |
|
2 |
7,220,473 |
Absorbing
agents and cover layer which is impermeable
to active substances and which contains
channel-formers or removable protective
layer of a transdermal therapeutic system
|
|
3 |
7,214,824 |
Substituted
N-sulfonylaminobenzyl-2-phenoxyacetamide
compounds as VR1 receptor agonists
|
|
4 |
7,199,151 |
DHA-pharmaceutical
agent conjugates of taxanes |
|
5 |
7,186,724 |
Heterocyclic
substituted carbonyl derivatives and their
use as dopamine D.sub.3 receptor ligands
|
|
6 |
7,122,683 |
Amides useful
as monoamine re-uptake inhibitors
|
|
7 |
7,122,198 |
Fast
dissolving composition with prolonged sweet
taste |
|
8 |
7,090,830 |
Drug
condensation aerosols and kits
|
|
9 |
7,053,092 |
5-HT1a
receptor subtype agonist |
|
10 |
7,040,314 |
Aerosol
generating devices and methods for
generating aerosols suitable for forming
propellant-free aerosols |
|
11 |
7,026,360 |
Pharmaceutical compositions containing
compounds with activity for the enhancement
of absorption of active ingredients
|
|
12 |
6,977,070 |
Buccal, polar
and non-polar spray or capsule containing
drugs for treating disorders of the central
nervous system |
|
13 |
6,964,962 |
Combinations
of reboxetine and neuroleptic agents
|
|
14 |
6,929,803 |
Conversion of
liquid filled gelatin capsules into
controlled release systems by multiple
coatings |
|
15 |
6,913,768 |
Sustained
release delivery of amphetamine salts
|
|
16 |
6,890,919 |
Atypical
antipsychotic agents having low affinity for
the D2 receptor |
|
17 |
6,861,072 |
Pharmaceutical composition with gastric
residence and controlled release
|
|
18 |
6,833,243 |
Methods for
selecting a therapy for a subject suffering
from schizophrenia |
|
19 |
6,713,089 |
Quick release
pharmaceutical compositions of drug
substances |
|
20 |
6,682,716 |
Delivery of
aerosols containing small particles through
an inhalation route |
|
21 |
6,680,047 |
Diagnostic/therapeutic agents
|
|
22 |
6,638,528 |
Compositions
and methods to effect the release profile in
the transdermal administration of active
agents |
|
23 |
6,602,902 |
Dha-pharmaceutical agent conjugates to
improve tissue selectivity |
|
24 |
6,599,529 |
Modified
release multiple-units compositions of
non-steroid anti-inflammatory drug
substances (NSAIDs) |
|
25 |
6,576,636 |
Method of
treating a liver disorder with fatty
acid-antiviral agent conjugates
|
|
26 |
6,566,065 |
Method of
diagnosing schizophrenia by detecting a
mutation in the (MTHFR) gene
|
|
27 |
6,562,363 |
Bioadhesive
compositions and methods for topical
administration of active agents
|
|
28 |
6,514,530 |
Dosage form
comprising means for changing drug delivery
shape |
|
29 |
6,419,952 |
Conversion of
liquid filled gelatin capsules into
controlled release systems by multiple
coatings |
|
30 |
6,331,289 |
Targeted
diagnostic/therapeutic agents having more
than one different vectors |
|
31 |
6,264,917 |
Targeted
ultrasound contrast agents |
|
32 |
6,261,537 |
Diagnostic/therapeutic agents having
microbubbles coupled to one or more vectors
|
|
33 |
6,221,383 |
Solubility
parameter based drug delivery system and
method for altering drug saturation
concentration |
|
34 |
6,210,712 |
Dosage form
having first and second coats
|
|
35 |
6,187,807 |
Methods of
use and compositions of (S) (-)-amisulpride
|
|
36 |
6,169,094 |
Compositions
of (S) (-)-amisulpride |
|
37 |
6,166,008 |
Treatment of
schizophrenia with ampakines and
neuroleptics |
|
38 |
6,150,353 |
Therapeutic
combinations of mirtazapine and
antipsychotic agents, for the treatment or
prophylaxis of psychotic disorders
|
|
39 |
6,069,165 |
Pharmaceutical compositions containing
amisulpride and their therapeutic
applications |
|
40 |
6,024,976 |
Solubility
parameter based drug delivery system and
method for altering drug saturation
concentration |
|
41 |
5,980,882 |
Drug-resin
complexes stabilized by chelating agents
|
|
42 |
5,795,909 |
DHA-pharmaceutical agent conjugates of
taxanes |
|
43 |
5,719,197 |
Compositions
and methods for topical administration of
pharmaceutically active agents
|
|
44 |
5,656,286 |
Solubility
parameter based drug delivery system and
method for altering drug saturation
concentration |
|
45 |
5,446,070 |
Compositions
and methods for topical administration of
pharmaceutically active agents
|
|
46 |
5,407,823 |
Polypeptides
having a dopaminergic receptor activity,
nucleic acids coding for these polypeptides
and use of these polypeptides for the
screening of substances active on these
polypeptides |
|
| |
| |
|
